VERAXA Biotech AG has entered a collaboration with Ardigen to enhance its BiTAC cancer therapeutics pipeline through AI-driven strategies.
On July 13, 2026, VERAXA Biotech AG announced its partnership with Ardigen S.A., an AI-focused company known for its contributions to precision medicine. This collaboration aims to advance VERAXA's BiTAC® pipeline, which includes T cell engagers (TCEs) and antibody drug conjugates (ADCs). A central aspect of this partnership is the integration of AI to improve drug development success rates, particularly in addressing the challenges posed by on-target, off-tumor toxicities associated with current high-potency therapies.
VERAXA's BiTAC platform employs a unique Boolean "AND-gate" logic that necessitates the simultaneous expression of two distinct targets on cancer cells for activation. This innovative mechanism is designed to enhance the therapeutic window while minimizing damage to healthy tissues. The collaboration with Ardigen will focus on developing AI-enabled tools to optimize the selection of synergistic cancer target pairs, leveraging extensive preclinical and clinical data to refine therapeutic designs.
Dr. Christoph Antz, CEO of VERAXA, emphasized the transformative potential of AI in guiding the development of BiTAC programs. He noted that effective target selection and validation at the outset could significantly impact success rates and product profiles, underscoring the strategic importance of this partnership in advancing precision oncology therapies.
This collaboration signifies a notable step in the integration of AI into drug discovery, potentially reshaping how cancer therapies are developed and improving outcomes for patients. As the industry increasingly adopts AI technologies, the implications for drug efficacy and safety could be profound, paving the way for more effective treatments.